Literature DB >> 19059938

Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia.

Brigitte Bader-Meunier1, Suzanne Verlhac, Monique Elmaleh-Bergès, Ghislaine Ithier, Fatiha Sellami, Sonia Faid, Florence Missud, Rolande Ducrocq, Corinne Alberti, Isabelle Zaccaria, Andre Baruchel, Malika Benkerrou.   

Abstract

This retrospective study assessed the long-term effect of transfusional exchange therapy on MRA/MRI abnormalities in 24 homozygous sickle-cell anemia (HbSS) children presenting with abnormal brain MRA. The median time elapsed from baseline to last available MRA was 29 months. Follow-up MRAs showed improvement, stabilization or worsening of cerebrovascular lesions in 11, 6 and 7 patients respectively. Complete normalization of MRA was observed in 6 patients within a mean time of 1.4 years, but stenosis recurred at the same location in the 4 patients in whom transfusion therapy was discontinued. Baseline severe stenosis/occlusion of large cerebral arteries and occurrence of moyamoya syndrome were significantly associated with an absence of improvement of the cerebral vasculopathy. These data emphasize the heterogeneity of the course of cerebrovasculopathy in SS children receiving chronic transfusion. Further studies are needed to determine whether different therapeutic approaches have to be considered according to these different evolutive patterns in SS children.

Entities:  

Mesh:

Year:  2008        PMID: 19059938      PMCID: PMC2625404          DOI: 10.3324/haematol.13610

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

1.  Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.

Authors:  Mark T Gladwin; James H Shelhamer; Frederick P Ognibene; Margaret E Pease-Fye; James S Nichols; Beth Link; Daksesh B Patel; Marcin A Jankowski; Lewis K Pannell; Alan N Schechter; Griffin P Rodgers
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

2.  Altered myocardial flow reserve and endothelial function late after Kawasaki disease.

Authors:  Hideto Furuyama; Yasuhisa Odagawa; Chietsugu Katoh; Yasuyoshi Iwado; Yoshinori Ito; Kazuyuki Noriyasu; Megumi Mabuchi; Keiichirou Yoshinaga; Yuji Kuge; Kunihiko Kobayashi; Nagara Tamaki
Journal:  J Pediatr       Date:  2003-02       Impact factor: 4.406

Review 3.  Pathophysiology and treatment of stroke in sickle-cell disease: present and future.

Authors:  Jeffrey A Switzer; David C Hess; Fenwick T Nichols; Robert J Adams
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

4.  Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Lena Coïc; Emmanuelle Lesprit; Pierre Brugières; Philippe Reinert
Journal:  Pediatr Radiol       Date:  2005-02-10

5.  Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study.

Authors:  Miguel R Abboud; Joel Cure; Suzanne Granger; Dianne Gallagher; Lewis Hsu; Winfred Wang; Gerald Woods; Brian Berman; Don Brambilla; Charles Pegelow; Jonathan Lewin; Robert A Zimmermann; Robert J Adams
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

6.  Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease.

Authors:  M O Russell; H I Goldberg; A Hodson; H C Kim; J Halus; M Reivich; E Schwartz
Journal:  Blood       Date:  1984-01       Impact factor: 22.113

7.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

Authors:  R J Adams; V C McKie; L Hsu; B Files; E Vichinsky; C Pegelow; M Abboud; D Gallagher; A Kutlar; F T Nichols; D R Bonds; D Brambilla
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

8.  Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.

Authors:  Sherri A Zimmerman; William H Schultz; Shelly Burgett; Nicole A Mortier; Russell E Ware
Journal:  Blood       Date:  2007-04-11       Impact factor: 22.113

9.  Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.

Authors:  C H Pegelow; R J Adams; V McKie; M Abboud; B Berman; S T Miller; N Olivieri; E Vichinsky; W Wang; D Brambilla
Journal:  J Pediatr       Date:  1995-06       Impact factor: 4.406

10.  High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease.

Authors:  W C Wang; E H Kovnar; I L Tonkin; R K Mulhern; J W Langston; S W Day; M J Schell; J A Wilimas
Journal:  J Pediatr       Date:  1991-03       Impact factor: 4.406

View more
  4 in total

Review 1.  Thalassemia and Moyamoya syndrome: unfurling an intriguing association.

Authors:  Shambaditya Das; Souvik Dubey; Mrinal Acharya; Subhankar Chatterjee; Durjoy Lahiri; Goutam Das; Biman Kanti Ray; Markus Kraemer
Journal:  J Neurol       Date:  2019-08-17       Impact factor: 4.849

2.  Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.

Authors:  Erin M Hall; Jeffrey Leonard; Jodi L Smith; Kristin P Guilliams; Michael Binkley; Robert J Fallon; Monica L Hulbert
Journal:  Pediatr Blood Cancer       Date:  2016-04-22       Impact factor: 3.167

3.  Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease.

Authors:  Monica L Hulbert; Robert C McKinstry; JoAnne L Lacey; Christopher J Moran; Julie A Panepinto; Alexis A Thompson; Sharada A Sarnaik; Gerald M Woods; James F Casella; Baba Inusa; Jo Howard; Fenella J Kirkham; Kofi A Anie; Jonathan E Mullin; Rebecca Ichord; Michael Noetzel; Yan Yan; Mark Rodeghier; Michael R Debaun
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 4.  Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.

Authors:  Françoise Bernaudin
Journal:  J Clin Med       Date:  2019-09-22       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.